According to a new report, published by KBV research, The Global Left Atrial Appendage (LAA) Closure Device Market size is expected to reach $4.0 billion by 2028, rising at a market growth of 19.3% CAGR during the forecast period.
The Hospital market is generating high revenue in the Global Left Atrial Appendage (LAA) Closure Device Market by End-use in 2021; thereby, achieving a market value of $2.3 Billion by 2028. In hospitals, epicardial LAA Closure Devices are utilized as an alternate therapy for atrial fibrillation. Depending on the patient's condition and requirements, this procedure can be performed via open surgery or percutaneous catheter-based procedures.
The Epicardial LAA Devices market is experiencing the highest CAGR of 21.6% during (2022 - 2028). Recently, epicardial LAA devices have emerged as an effective method for preventing strokes in individuals with atrial fibrillation who are not adherent to long-term oral anticoagulants. Short-term follow-up data indicate that epicardial LAA devices reduce the severity of atrial fibrillation and thus, are linked with an early and consistent decrease in systemic blood pressure.
The North America market dominated the Global Left Atrial Appendage (LAA) Closure Device Market by Region in 2021; thereby, achieving a market value of $1.5 billion by 2028. The Europe market is exhibiting a CAGR of 18.6% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 20.5% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/left-atrial-appendage-closure-device-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Johnson & Johnson (Johnson & Johnson Services, Inc.), Occlutech Holding AG, LifeTech Scientific Corporation, Cardia, Inc. and Lepu Medical Technology Co., Ltd
By End-use
By Product
By Geography
Companies Profiled
Unique Offerings 
